Results
|
|
1.
|
|
|
|
2.
|
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. MedStar authors:
Year: 2019
Citation: - The Lancet Diabetes & Endocrinology. 7(8):596-605, 2019 08.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Gonzalez-Galvez G, Gron R, Halladin N, Haluzik M, Jermendy G, Kok A, Orsy P, Sabbah M, Sesti G, Silver R
|
|
|
3.
|
Testosterone and depressive symptoms among men in the Diabetes Prevention Program. MedStar authors:
Year: 2016
Citation: - Psychoneuroendocrinology. 72:63-71, 2016 Oct
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Barrett-Connor E, Bray GA, Christophi CA, Diabetes Prevention Program Research Group, Golden SH, Horton ES, Kim C, Labrie F, Mather KJ, Pi-Sunyer X
|
|
|
4.
|
|
|
|
5.
|
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. MedStar authors:
Year: 2017
Citation: - Diabetes, Obesity & Metabolism. 19(10):1408-1415, 2017 Oct.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bergenstal RM, Bonadonna RC, Kapitza C, LixiLan-L trial investigators, Niemoeller E, Puig-Domingo M, Souhami E, Stager W, Wysham C, Yu C
|
|
|
6.
|
|
|
|
7.
|
Neuropsychiatric safety with liraglutide 3.0mg for weight management: results from randomized controlled phase 2 and 3a trials. MedStar authors:
Year: 2017
Citation: - Diabetes, Obesity & Metabolism. 19(11):1529-1536, 2017 Nov.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Astrup A, Brett J, Cancino A, Kushner R, Lau DC, O'Neil PM, Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups, Wadden TA, Wilding JP
|
|
|
8.
|
Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. MedStar authors:
Year: 2020
Citation: - Diabetes Care. 43(5):940-947, 2020 05.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Butera NM, Camp AW, Cherrington A, Craig J, Fortmann SP, GRADE Research Group, Hollander PA, Krakoff J, Perez M, Phillips LS, Rasouli N, Sivitz WI, Tan MH, Tiktin M, Wexler DJ, Younes N
|
|
|
9.
|
Higher burden of cardiometabolic and socioeconomic risk factors in women with type 2 diabetes: an analysis of the Glycemic Reduction Approaches in Diabetes (GRADE) baseline cohort. MedStar authors:
Year: 2023
Citation: - BMJ Open Diabetes Research & Care. 11(2), 2023 04.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - AbouAssi H, Ahmann AJ, Aroda VR, Butera NM, Desouza C, Green JB, Gulanski BI, Harindhanavudhi T, Krause-Steinrauf H, Lichtman JH, Suratt CE, Wexler DJ
|
|
|
10.
|
Effects of weight loss, weight cycling, and weight loss maintenance on diabetes incidence and change in cardiometabolic traits in the Diabetes Prevention Program. MedStar authors:
Year: 2014
Citation: - Diabetes Care. 37(10):2738-45, 2014 Oct.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Observational Study
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Aroda VR, Bray GA, Delahanty LM, Diabetes Prevention Program Research Group, Florez JC, Franks PW, Jablonski KA, Kahn SE, Pan Q, Perreault L, Watson KE
|
|
|
11.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(9):1579-86, 2016 Sep
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Diamant M, Fonseca V, LixiLan PoC Study Group, Perfetti R, Rosenstock J, Silvestre L, Souhami E, Zhou T
|
|
|
12.
|
Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. [Review] MedStar authors:
Year: 2017
Citation: - Diabetologia. 60(9):1601-1611, 2017 Sep.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Crandall JP, Darwin C, Diabetes Prevention Program Research Group, Edelstein SL, Heckman-Stoddard BM, Jeffries SL, Kahn SE, Knowler WC, Molitch ME, Nathan DM, Perreault L, Pi-Sunyer X, Temprosa M
|
|
|
13.
|
Androgens, irregular menses, and risk of diabetes and coronary artery calcification in the Diabetes Prevention Program. MedStar authors:
Year: 2018
Citation: - Journal of Clinical Endocrinology & Metabolism. 103(2):486-496, 2018 02 01.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Carrion-Petersen M, Diabetes Prevention Program Outcomes Study Group, Edelstein SL, Ehrmann DA, Goldberg RB, Kim C, Younes N
|
|
|
14.
|
Lower skin cancer risk in women with higher body mass index: the women's health initiative observational study. MedStar authors:
Year: 2013
Citation: - Cancer Epidemiology, Biomarkers & Prevention. 22(12):2412-5, 2013 Dec.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
All authors: - Aroda V, Desai M, Henderson MT, Hernandez-Boussard T, Kubo J, McTiernan A, Sims ST, Stefanick ML, Tang JY, Thomas F
|
|
|
15.
|
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. MedStar authors:
Year: 2018
Citation: - Diabetes Care. 41(2):258-266, 2018 02.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Ahmann AJ, Annett MP, Aroda VR, Capehorn M, Charpentier G, Dotta F, Henkel E, Holst AG, Lingvay I
|
|
|
16.
|
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. MedStar authors:
Year: 2019
Citation: - Diabetes Care. 42(11):2108-2116, 2019 11.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Blonde L, Del Prato S, Frias J, Henry R, Ji C, Niemoeller E, Rosenstock J, Shehadeh N, Souhami E
|
|
|
17.
|
Establishing an electronic health record-supported approach for outreach to and recruitment of persons at high risk of type 2 diabetes in clinical trials: The vitamin D and type 2 diabetes (D2d) study experience. MedStar authors:
Year: 2019
Citation: - Clinical Trials. 16(3):306-315, 2019 06.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Brodsky IG, Chadha C, Chatterjee R, D2d Research Group, Desouza C, LeBlanc ES, Ouellette MG, Phillips LS, Pittas AG, Sheehan PR, Staten MA, Vickery EM
|
|
|
18.
|
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. MedStar authors:
Year: 2018
Citation: - The Lancet Diabetes & Endocrinology. 6(4):275-286, 2018 04.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Andreassen C, Aroda VR, Lingvay I, Ludemann J, Navarria A, Pratley RE, SUSTAIN 7 investigators, Viljoen A
|
|
|
19.
|
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. MedStar authors:
Year: 2019
Citation: - Diabetes Care. 42(9):1724-1732, 2019 09.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Altuntas Y, Aroda VR, Christiansen E, Haluzik M, Hertz CL, Jeppesen OK, Lalic NM, Morales Villegas EC, PIONEER 1 Investigators, Rosenstock J, Terauchi Y
|
|
|
20.
|
Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).[Erratum appears in Diabetes Obes Metab. 2016 Sep;18(9):952; PMID: 27546838] MedStar authors:
Year: 2016
Citation: - Diabetes, Obesity & Metabolism. 18(7):663-70, 2016 Jul
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Andersen TH, Aroda VR, Bailey TS, Cariou B, Kumar S, Leiter LA, Philis-Tsimikas A, Raskin P, Zacho J
|
|
|
21.
|
Analysis of metabolic syndrome components in >15 000 african americans identifies pleiotropic variants: results from the population architecture using genomics and epidemiology study. MedStar authors:
Year: 2014
Citation: - Circulation. Cardiovascular Genetics. 7(4):505-13, 2014 Aug.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Meta-Analysis
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Aroda V, Bhattacharjee S, Carlson CS, Carty CL, Chatterjee N, Cheng I, Haessler J, Hindorff LA, Hsu CN, Jackson R, Kooperberg C, Liu S, North KE, Pankow JS, Peters U, Selvin E, Wilkens L
|
|
|
22.
|
Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. MedStar authors:
Year: 2019
Citation: - Diabetes Technology & Therapeutics. 21(5):273-285, 2019 May.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bailey TS, Bergenstal RM, Brazg RL, Calibra Study Group, Dreon DM, Frias JP, Johnson ML, Klonoff DC, Kruger DF, Levy BL, Naik RG, Peyrot M, Ramtoola S, Rosenstock J, Serusclat P, Shearer DM, Weinstock RS, Zraick V
|
|
|
23.
|
Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. MedStar authors:
Year: 2016
Citation: - Journal of Clinical Endocrinology & Metabolism. 101(4):1754-61, 2016 Apr
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - Aroda VR, Bray GA, Crandall JP, Diabetes Prevention Program Research Group, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, Schade DS, Temprosa MG, White NH
|
|
|
24.
|
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. MedStar authors:
Year: 2017
Citation: - The Lancet Diabetes & Endocrinology. 5(5):355-366, 2017 May
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Axelsen M, Bain SC, Cariou B, DeVries JH, Piletic M, Rose L, Rowe E
|
|
|
25.
|
Steroid Sex Hormones, Sex Hormone-Binding Globulin, and Diabetes Incidence in the Diabetes Prevention Program. MedStar authors:
Year: 2015
Citation: - Journal of Clinical Endocrinology & Metabolism. 100(10):3778-86, 2015 Oct.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, P.H.S.
All authors: - Aroda VR, Barrett-Connor E, Christophi CA, Diabetes Prevention Program, Edelstein SE, Florez JC, Goldberg RB, Kahn SE, Kim C, Knowler WC, Labrie F, Mather KJ
|
|
|
26.
|
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. MedStar authors:
Year: 2019
Citation: - Diabetes Care. 42(12):2262-2271, 2019 12.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Araki E, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, PIONEER 8 investigators, Tarp-Johansen MJ, Zinman B
|
|
|
27.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(11):1972-1980, 2016 Nov
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bellido D, Bergenstal RM, Gonzalez-Galvez G, Guo H, LixiLan-L Trial Investigators, Niemoeller E, Rosenstock J, Souhami E, Takami A, Unger J, Wysham C
|
|
|
28.
|
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). MedStar authors:
Year: 2017
Citation: - Diabetic Medicine. 34(12):1747-1755, 2017 Dec.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Barrett-Connor E, Dabelea D, Dagogo-Jack S, Hamman RF, Kahn SE, Knowler WC, Mather KJ, Pan Q, Perreault L, The Diabetes Prevention Program Research Group
|
|
|
29.
|
|
|
|
30.
|
Differences in complications, cardiovascular risk factor, and diabetes management among participants enrolled at veterans affairs (VA) and non-VA medical centers in the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE). MedStar authors:
- Aroda, Vanita R
- Park, Jean
Year: 2022
Citation: - Diabetes Research & Clinical Practice. 184:109188, 2022 Feb.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Florez HJ, Ghosh A, GRADE Research Group, Hox SH, Killean T, Krause-Steinrauf H, McKee MD, Park J, Pop-Busui R, Rhee MK, Underkofler C, Wexler DJ
|
|
|
31.
|
|
|
|
32.
|
The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. MedStar authors:
- Aroda, Vanita R
- Ratner, Robert E
Year: 2015
Citation: - Journal of Clinical Endocrinology & Metabolism. 100(4):1646-53, 2015 Apr.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Observational Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
All authors: - Ackermann RT, Aroda VR, Barrett-Connor E, Christophi CA, Delahanty LM, Diabetes Prevention Program Research Group, Edelstein SL, Herman WH, Knowler WC, Montez MG, Ratner RE, Zhang P, Zhuo X
|
|
|
33.
|
|
|
|
34.
|
|
|
|
35.
|
Cross-sectional evaluation of noninvasively detected skin intrinsic fluorescence and mean hemoglobin a1c in type 1 diabetes. MedStar authors:
- Aroda, Vanita R
- Fernandez, Stephen J
- Ratner, Robert E
Year: 2013
Citation: - Diabetes Technology & Therapeutics. 15(2):117-23, 2013 Feb.
Institution:
- MedStar Health Research Institute
- MedStar Heart & Vascular Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Aroda VR, Conway BN, Fernandez SJ, Matter NI, Maynard JD, Orchard TJ, Ratner RE
|
